Affiliation:
1. Jalpaiguri Government Engineering Collge
2. Punjab Engineering College
3. Stevens Institute of Technology
4. State University of New York at Buffalo
Abstract
Abstract
The call for implementing inhibitory methods in cancer treatment has intensified. Recently, cancer has deeply affected society, with Acute Myeloid Leukemia (AML) being identified as one of the most formidable and lethal adversaries. This research investigates the intricate interactions between vitamins A, B, C, D, E, and K and critical signaling pathways, such as NPM1, FLT3, and RUNX1, uncovering meaningful associations. Employing the precision of molecular docking with Autodock Vina 1.5.7, a thorough exploration of these interactions was carried out. The analysis entailed a detailed examination of hydrophilic and hydrophobic aspects using LigPlot, complemented by additional insights visualized through PyMol. The considerable occurrence of observed hydrophilic interactions, coupled with the noteworthy binding energy, underscores the potential of vitamin-related derivatives as promising contenders for inhibitory cancer treatments. However, the realization of this potential is contingent upon subsequent investigations, including a comprehensive exploration through RT-qPCR studies. While the study has successfully identified significant interactions, the intricate dynamics of gene expression necessitate thorough studies to attain a holistic understanding of both upregulation and downregulation. In conclusion, the revelations from this study not only set the stage for potential inhibitory treatments of AML through the strategic application of vitamin-based derivatives but also underscore the transformative capabilities of these derivatives. In future research endeavors, should vitamin interactions reveal substantial downregulation, these derivatives stand poised to spearhead innovative cancer treatments, marking a transformative era in targeted drug delivery.
Publisher
Research Square Platform LLC
Reference57 articles.
1. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.”;Sung Hyuna;CA: A Cancer Journal for Clinicians,2021
2. Perillo, Bruno, et al. “ROS in Cancer Therapy: The Bright Side of the Moon.” Experimental & Molecular Medicine, vol. 52, no. 2, Feb. 2020, pp. 192–203. www.nature.com, https://doi.org/10.1038/s12276-020-0384-2
3. FDA Approves Vanflyta for FLT3-Mutated AML - NCI. 15 Aug. 2023, https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3
4. Whiteley, Andrew E., et al. ‘Leukaemia: A Model Metastatic Disease’. Nature Reviews. Cancer, vol. 21, no. 7, July 2021, pp. 461–75. PubMed Central, https://doi.org/10.1038/s41568-021-00355-z
5. AML Survival Rates by Age in Adults and Children. 27 June 2023, https://www.medicalnewstoday.com/articles/aml-survival-rates